Andra AP fonden boosted its stake in shares of Elanco Animal Health (NYSE:ELAN) by 17.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 131,500 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Andra AP fonden’s holdings in Elanco Animal Health were worth $3,497,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of ELAN. Commonwealth Equity Services LLC boosted its position in Elanco Animal Health by 24.3% during the second quarter. Commonwealth Equity Services LLC now owns 19,351 shares of the company’s stock valued at $654,000 after purchasing an additional 3,789 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Elanco Animal Health by 52.3% during the second quarter. State of Alaska Department of Revenue now owns 56,856 shares of the company’s stock valued at $1,921,000 after purchasing an additional 19,529 shares during the last quarter. Arizona State Retirement System acquired a new position in Elanco Animal Health during the second quarter valued at approximately $2,611,000. Mn Services Vermogensbeheer B.V. boosted its position in Elanco Animal Health by 191.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 142,070 shares of the company’s stock valued at $4,802,000 after purchasing an additional 93,400 shares during the last quarter. Finally, Strs Ohio acquired a new position in Elanco Animal Health during the second quarter valued at approximately $870,000. 98.43% of the stock is owned by hedge funds and other institutional investors.
Several analysts have issued reports on the company. Cleveland Research restated a “hold” rating on shares of Elanco Animal Health in a research note on Thursday, September 26th. Barclays assumed coverage on Elanco Animal Health in a research note on Monday, September 23rd. They issued an “overweight” rating and a $36.00 price objective on the stock. Zacks Investment Research lowered Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Goldman Sachs Group assumed coverage on Elanco Animal Health in a research note on Monday, September 9th. They issued a “positive” rating on the stock. They noted that the move was a valuation call. Finally, Morgan Stanley upgraded Elanco Animal Health from an “equal” rating to a “weight” rating and dropped their price objective for the company from $34.00 to $32.00 in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Elanco Animal Health presently has a consensus rating of “Hold” and a consensus target price of $33.19.
NYSE:ELAN opened at $27.62 on Tuesday. The company has a quick ratio of 1.67, a current ratio of 3.12 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average price is $26.87 and its two-hundred day moving average price is $29.67. The firm has a market capitalization of $10.34 billion, a price-to-earnings ratio of 24.74 and a beta of 0.71. Elanco Animal Health has a 12-month low of $25.25 and a 12-month high of $35.46.
Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.04. The firm had revenue of $771.30 million for the quarter, compared to analyst estimates of $765.85 million. Elanco Animal Health had a return on equity of 7.79% and a net margin of 3.04%. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.29 earnings per share. Equities research analysts expect that Elanco Animal Health will post 1.07 EPS for the current year.
In other news, major shareholder Dawei Li bought 1,384,717 shares of the stock in a transaction dated Wednesday, September 4th. The shares were bought at an average price of $1.05 per share, for a total transaction of $1,453,952.85. Also, insider Todd S. Young bought 10,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $26.57 per share, for a total transaction of $265,700.00. Following the purchase, the insider now owns 28,883 shares of the company’s stock, valued at approximately $767,421.31. The disclosure for this purchase can be found here. Insiders acquired 1,475,461 shares of company stock worth $3,864,853 in the last 90 days. Corporate insiders own 0.04% of the company’s stock.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Featured Story: Quiet Period Expirations Explained
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.